Replicating and non-replicating viral vectors for vaccine development
Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as fact...
Gespeichert in:
| Veröffentlicht in: | Current opinion in biotechnology 2007-12, Vol.18 (6), p.546-556 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 556 |
|---|---|
| container_issue | 6 |
| container_start_page | 546 |
| container_title | Current opinion in biotechnology |
| container_volume | 18 |
| creator | Robert-Guroff, Marjorie |
| description | Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity. |
| doi_str_mv | 10.1016/j.copbio.2007.10.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2245896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0958166907001322</els_id><sourcerecordid>20264575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c613t-537c003b415b62c7078dff0bdefdce53a6cafba5a804d7811581c855b5c83b593</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EokvhHyCUE7csYzv-yAUJVQUqVULi42w5zqR4ydrBzkbqv6-jXdGWS0-WxvO-8_EMIW8pbClQ-WG3dXHqfNwyAFVCW6DwjGyoVm0NDWufkw20QtdUyvaMvMp5BwCCK3hJzqgGyblQG3L5HafROzv7cFPZ0Fchhjo9iC0-2bFa0M0x5WqIqVqscz5g1eOCY5z2GObX5MVgx4xvTu85-fX58ufF1_r625eri0_XtZOUz3Wp7gB411DRSeYUKN0PA3Q9Dr1Dwa10duissBqaXmlKhaZOC9EJp3knWn5OPh59p0O3x6IJc-nOTMnvbbo10Xrz-Cf43-YmLoaxRuhWFoP3J4MU_x4wz2bvs8NxtAHjIRvZQsta3jyZyIDJRihREptjoksx54TDv24omBWU2ZkjKLOCWqMFVJG9ezjJvehE5n5ULPtcPCaTncfgsPepwDB99E9V-N_AjT4UrOMfvMW8i4cUCitDTWYGzI_1WNZbAQVAOWP8DsVavNY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20264575</pqid></control><display><type>article</type><title>Replicating and non-replicating viral vectors for vaccine development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Robert-Guroff, Marjorie</creator><creatorcontrib>Robert-Guroff, Marjorie</creatorcontrib><description>Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity.</description><identifier>ISSN: 0958-1669</identifier><identifier>EISSN: 1879-0429</identifier><identifier>DOI: 10.1016/j.copbio.2007.10.010</identifier><identifier>PMID: 18063357</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>AIDS Vaccines - genetics ; AIDS Vaccines - immunology ; Animals ; Genetic Vectors - genetics ; Human immunodeficiency virus ; Humans ; Internal Medicine ; Technology, Pharmaceutical - methods ; Viral Vaccines - genetics ; Viral Vaccines - immunology ; Virus Replication ; Viruses - genetics ; Viruses - growth & development ; Viruses - immunology</subject><ispartof>Current opinion in biotechnology, 2007-12, Vol.18 (6), p.546-556</ispartof><rights>2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c613t-537c003b415b62c7078dff0bdefdce53a6cafba5a804d7811581c855b5c83b593</citedby><cites>FETCH-LOGICAL-c613t-537c003b415b62c7078dff0bdefdce53a6cafba5a804d7811581c855b5c83b593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0958166907001322$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18063357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robert-Guroff, Marjorie</creatorcontrib><title>Replicating and non-replicating viral vectors for vaccine development</title><title>Current opinion in biotechnology</title><addtitle>Curr Opin Biotechnol</addtitle><description>Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity.</description><subject>AIDS Vaccines - genetics</subject><subject>AIDS Vaccines - immunology</subject><subject>Animals</subject><subject>Genetic Vectors - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Technology, Pharmaceutical - methods</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><subject>Virus Replication</subject><subject>Viruses - genetics</subject><subject>Viruses - growth & development</subject><subject>Viruses - immunology</subject><issn>0958-1669</issn><issn>1879-0429</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1v1DAQhi0EokvhHyCUE7csYzv-yAUJVQUqVULi42w5zqR4ydrBzkbqv6-jXdGWS0-WxvO-8_EMIW8pbClQ-WG3dXHqfNwyAFVCW6DwjGyoVm0NDWufkw20QtdUyvaMvMp5BwCCK3hJzqgGyblQG3L5HafROzv7cFPZ0Fchhjo9iC0-2bFa0M0x5WqIqVqscz5g1eOCY5z2GObX5MVgx4xvTu85-fX58ufF1_r625eri0_XtZOUz3Wp7gB411DRSeYUKN0PA3Q9Dr1Dwa10duissBqaXmlKhaZOC9EJp3knWn5OPh59p0O3x6IJc-nOTMnvbbo10Xrz-Cf43-YmLoaxRuhWFoP3J4MU_x4wz2bvs8NxtAHjIRvZQsta3jyZyIDJRihREptjoksx54TDv24omBWU2ZkjKLOCWqMFVJG9ezjJvehE5n5ULPtcPCaTncfgsPepwDB99E9V-N_AjT4UrOMfvMW8i4cUCitDTWYGzI_1WNZbAQVAOWP8DsVavNY</recordid><startdate>20071201</startdate><enddate>20071201</enddate><creator>Robert-Guroff, Marjorie</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20071201</creationdate><title>Replicating and non-replicating viral vectors for vaccine development</title><author>Robert-Guroff, Marjorie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c613t-537c003b415b62c7078dff0bdefdce53a6cafba5a804d7811581c855b5c83b593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>AIDS Vaccines - genetics</topic><topic>AIDS Vaccines - immunology</topic><topic>Animals</topic><topic>Genetic Vectors - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Technology, Pharmaceutical - methods</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><topic>Virus Replication</topic><topic>Viruses - genetics</topic><topic>Viruses - growth & development</topic><topic>Viruses - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robert-Guroff, Marjorie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robert-Guroff, Marjorie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Replicating and non-replicating viral vectors for vaccine development</atitle><jtitle>Current opinion in biotechnology</jtitle><addtitle>Curr Opin Biotechnol</addtitle><date>2007-12-01</date><risdate>2007</risdate><volume>18</volume><issue>6</issue><spage>546</spage><epage>556</epage><pages>546-556</pages><issn>0958-1669</issn><eissn>1879-0429</eissn><abstract>Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>18063357</pmid><doi>10.1016/j.copbio.2007.10.010</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0958-1669 |
| ispartof | Current opinion in biotechnology, 2007-12, Vol.18 (6), p.546-556 |
| issn | 0958-1669 1879-0429 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2245896 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | AIDS Vaccines - genetics AIDS Vaccines - immunology Animals Genetic Vectors - genetics Human immunodeficiency virus Humans Internal Medicine Technology, Pharmaceutical - methods Viral Vaccines - genetics Viral Vaccines - immunology Virus Replication Viruses - genetics Viruses - growth & development Viruses - immunology |
| title | Replicating and non-replicating viral vectors for vaccine development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T21%3A51%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Replicating%20and%20non-replicating%20viral%20vectors%20for%20vaccine%20development&rft.jtitle=Current%20opinion%20in%20biotechnology&rft.au=Robert-Guroff,%20Marjorie&rft.date=2007-12-01&rft.volume=18&rft.issue=6&rft.spage=546&rft.epage=556&rft.pages=546-556&rft.issn=0958-1669&rft.eissn=1879-0429&rft_id=info:doi/10.1016/j.copbio.2007.10.010&rft_dat=%3Cproquest_pubme%3E20264575%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20264575&rft_id=info:pmid/18063357&rft_els_id=S0958166907001322&rfr_iscdi=true |